Endocrine Abstracts

Secondary hyperparathyroidism (SHPT) as well as vitamin D deficiency are highly prevalent in patients with chronic kidney disease (CKD). Traditional therapy of SHPT includes administration of calcitriol, mainly in dialysis patients. Data about effects of native vitamin D repletion in such patients are still inconsistent. The aim was to assess effects of vitamin D repletion in CKD patients with SHPT and vitamin D deficiency. 88 patients, mean age 50.8±14.6 years with CKD 3...

Secondary (SHPT) is frequent in patients with chronic kidney disease and can predispose patients to low bone mineral density (BMD). Necessity of BMD assessment in such patients is controversial.The aim was to analyze BMD and PTH secretion in patients with different stages of chronic kidney disease. We examined 311 patients, 161 f, 150 m; age 49.2±14.4 yrs; 190 patients are on continuous dialysis due to end-stage chronic kidney disease (mean dialysis...

The aim was to estimate Vitamin D3 (25OHD) level and it’s relation to secondary hyperparathyroidism (SHPT) development in patients with different stages of chronic kidney disease (CKD).We examined 114 patients, 71 f, 43 m; age 44.6±14.3 years. CKD stage was defined by estimated glomerular filtration rate (eGFR) calculated by MDRD formula. 48 patients have CKD stage 1–2, 26 pts – CKD3, 27 pts – CKD4, 13 pts – CKD5 (not on dia...

The aim was to analyse dynamics of PTH secretion in dialysis patients during different period of observation and to determine factors of secondary hyperparathyroidism progression. We examined 92 patients, 52f, 40m; age 47.2±11.4 years; dialysis duration 4.9±3.9 years; mean observational period 8.9±4.3 months (6–24). Serum PTH, 25(OH)D3, osteocalcin (OC), C-terminal telopeptide of type I collagen (β-CTx), alkaline phosphotase (ALP), calcium (Ca), and ph...

Secondary hyperparathyroidism (SHPT) is common in patients with chronic kidney disease (CKD). The aim of the study was to analyze dynamics of PTH secretion during 1 year of observation of patients with CKD stage 3 and 4. We examined 40 patients, 22 f, 18 m; age 55.9±14.5 years. Mean glomerular filtration rate (GFR)? Calculated by MDRD formula was 27.2±15.7 ml/min; 15 patients have CKD stage 3, 25 – stage 4. Serum PTH, 25(OH)D3, calcium (Ca) and phosphorus (P) we...

It’s well known that secondary hyperparathyroidism (SHPT) is common in patients with chronic kidney disease stage 5 (CKD5D), on dialysis. The aim of our study was to analyze peculiarities of SHPT in diabetic patients in comparison to those with other course of CKD5D.We studied 25 diabetic and 180 non-diabetic patients with CKD5D, mean age 47.5±10.8 years; age at dialysis onset 42.7±11.7 years; dialysis duration 4.7±3.9 years. Groups w...

Aims: Thyroid status disturbances are not rare among DKD patients. It is known that the genesis of anemia in DKD has a multifactorial nature, and the combination of DKD and anemia significantly impairs quality of life. In addition, anemia in diabetic patients with DKD occurs earlier and tends to be more severe compared with CKD patients without diabetes. The purpose of the study was to investigate potential relationship between thyroid status and iron metabolism profile in pat...

Secondary hyperparathyroidism is highly prevalent in patients with end-stage chronic kidney disease (CKD). Optimal range of PTH level for this cohort of patients is still controversial. The aim of the study was to use a neural network algorithm to determine the optimal point value and confidence interval for the average PTH value for patients with end-stage chronic kidney disease to maintain bone metabolism.The study included 190 patients with end-stage ...

Aims: Thyroid function changes are common endocrine disturbance among patients with chronic kidney disease (CKD), including those receiving renal replacement therapy (RRT). The purpose of the study was to study the effect of RRT on thyroid function in patients with type 1 diabetes (T1D).Materials and methods: Thyroid hormone examination was performed before and after hemodialysis procedures (HD) in 9 patients with T1D (3 men and 6 women). Mean age was 41...

AimsDiabetic nephropathy (DN) is a leading cause of chronic kidney disease (CKD). Renal impairment may affect not only glycemic control, but also metabolism of biologically active cytokines such as adiponectin. Taking into account multiple effects of adiponectin the purpose of the study was to assess its changes in patients with type 1 diabetes (T1D) and comorbid CKD.Materials and methodsWe recruited 129 pati...